Tom Frohlich, Chief Executive Officer at Jade Biosciences, Inc. (JBIO), bought 6,000 shares at $7.40 ($44K) on 2025-05-16, disclosed to the SEC on 2025-05-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| KDNY | SELL | 2022-12-15 | $250K | — | Filing → |
| KDNY | SELL | 2022-11-09 | $222K | — | Filing → |
| KDNY | SELL | 2022-10-11 | $290K | — | Filing → |